The shock success of GLP-1 treatments for obesity carries massive implications (https://www.breakingviews.com/columns/considered-view/obesity-drugs-everyone-is-double-edged-sword-2025-05-29/) for wealthy societies and manufacturers Novo Nordisk (https://www.breakingviews.com/columns/breaking-view/novo-nordisks-skinny-pipeline-demands-bulky-cure-2025-08-06/) and Eli Lilly alike. In this week’s Viewsroom podcast, Breakingviews columnists discuss how this would-be jackpot (https://www.breakingviews.com/columns/considered-view/big-pharma-has-rare-shot-bargain-hunting-2025-08-11/) has companies running to keep up.
Visit the Thomson Reuters Privacy Statement (https://www.thomsonreuters.com/en/privacy-statement.html) for information on our privacy and data protection practices. You may also visit megaphone.fm/adchoices (https://megaphone.spotify.com/about-advertisements) to opt-out of targeted advertising.
Learn more about your ad choices. Visit megaphone.fm/adchoices (https://megaphone.fm/adchoices)
